PIONEER STUDY PRECISION IMMUNO-ONCOLOGY FOR ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH PD1/L1 ICI RESISTANCE


1 Aix Marseille University (AMU) and Assistance Publique des Hôpitaux de Marseille (APHM), Marseille/France, 2 Centre Léon Bérard, Lyon/France, 3 CHU Toulouse/France, 4 Department of Thoracic Oncology, Centre Léon Bérard, Lyon/France, 5 AstraZeneca, Baar/Switzerland, 6 HalloXy, Marseille/France, 7 Hôpital Sainte-Musse, Toulon/France, 8 Centre Hospitalier Jean Rougier, Cahors/France, 9 UIMA Pneumologique CHdV, Foix/France, 10 Hôpital Nord Ouest, Villefranche sur Saône, 11 Gilead Sciences, Hôpital Beaujon, Clichy/France, 12 Polytechnical Mayord, Istres/France, 13 Centre Hospitalier Arnaud de Villeneuve, Amiens/France, 14 Wosital Européen, Marseille/France, 15 Centre Hospitalier Montauban/France, 16 AMU, Marseille/France, 17 Cancer Research Center of Marseille, AMU, Inserm, CNRS, Institut Paoli-Calmettes, Marseille/France, 18 AMU, CNRS, Inserm, Centre d’Immunologie de Marseille Luminy, APHM, Inrate Pharma, Marseille/France.

This work is supported by French National Research Agency (17-RNCE-007), a partnership of AMU, AP-HM, CNRS, Inserm, Centre Léon Bérard, Institut Paoli-Calmettes, AstraZeneca, HalloXy, Inrate Pharma & ImCheck Therapeutics, sponsored by AP-HM and initiated by Marseille Immunopole. Drug supply is funded by Inrate Pharma & AstraZeneca.

PIONEER study (as of June 30, 2019)

PIONEER randomized umbrella trial

NCT03833440: FPV: July, 2019 (inclusion on, 24 months); LPLV: Q4 2022, 3 centers in France.

PIONEER biomarkers program (logistics)


Multiparametric biomarkers analysis

- Blood: circulating immune effector cells, cytokines, endothelial activation, PK-PD relationships
- Tumors & Microenvironment: immunomodulatory status (dual/multiplex IHC, digital pathology: ImmunoCORE® IC, Brightplex), tumor foreignness (NGS: TMB, T cell clonality); immune profile (RNAseq)
- Feces: impact of gut microbiome in ICIs resistance.

Next steps

1st administration within the PIONEer trial (Q3 2019).

New centers in France (Q3-Q4 2019).

References

- Saad ED et al. Nat Rev Clin Oncol 2017
- Herbst R et al. ESMO IO 2018
- Vokes E et al. Ann Oncol 2018
- Gide TN et al. CCR 2018